Publications

Search

June 25, 2013 | Diabetes.
Hagopian Lab

Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial

William Hagopian, Robert J Ferry Jr, Nicole Sherry, David Carlin, Ezio Bonvini, Syd Johnson, Kathryn E Stein, Scott Koenig, Anastasia G Daifotis, Kevan C Herold, Johnny Ludvigsson; Protégé Trial Investigators

May 12, 2011 | Pediatr Diabetes.
Hagopian Lab

The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants

William A Hagopian, Henry Erlich, Ake Lernmark, Marian Rewers, Anette G Ziegler, Olli Simell, Beena Akolkar, Robert Vogt Jr, Alan Blair, Jorma Ilonen, Jeffrey Krischer, JinXiong She; TEDDY Study Group

May 30, 2002 | N Engl J Med.
Hagopian Lab

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

Kevan C Herold, William Hagopian, Julie A Auger, Ena Poumian-Ruiz, Lesley Taylor, David Donaldson, Stephen E Gitelman, David M Harlan, Danlin Xu, Robert A Zivin, Jeffrey A Bluestone

January 1, 1993 | J Clin Invest.
Hagopian Lab

Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type

W A Hagopian, A E Karlsen, A Gottsäter, M Landin-Olsson, C E Grubin, G Sundkvist, J S Petersen, E Boel, T Dyrberg, and A Lernmark

October 1, 1991 | Proc Natl Acad Sci USA.
Hagopian Lab

Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10

A E Karlsen, W A Hagopian, C E Grubin, S Dube, C M Disteche, D A Adler, H Bärmeier, S Mathewes, F J Grant, D Foster, Åke Lernmark